Mark J. Gilbert, M.D. is the chief medical officer at Juno Therapeutics, where he joined in March 2014. Prior to joining Juno, Dr. Gilbert served as an interim chief medical officer and consultant in strategic drug development and portfolio management in medical oncology for several U.S. biotechnology and pharmaceutical companies.
Previously, Dr. Gilbert served as vice president, head of global clinical development, therapeutic area oncology, at Bayer Schering Pharmaceuticals. Prior to Bayer Schering, Dr. Gilbert held several executive positions with Berlex Pharmaceuticals as well as at its parent company Schering, AG, as vice president, head of global medical development group, oncology. Dr. Gilbert joined Berlex from Immunex, where his responsibilities included development and medical affairs for leukine and mitoxantrone in hematology, oncology, Crohn’s disease and multiple sclerosis.
Prior to his executive positions in biotech and oncology companies, Dr. Gilbert was a faculty member at the Fred Hutchinson Cancer Research Center and the University of Washington in Seattle and trained in the laboratory of Dr. Phil Greenberg, one of Juno’s scientific co-founders.
Dr. Gilbert earned a bachelor of science degree in biochemistry from the University of Iowa and a medical doctor degree from the University of Iowa Medical School in Iowa City, Iowa. He trained in internal medicine, infectious disease and medical oncology at the University of California, San Francisco, and at the University of Washington in Seattle.